OBJECTIVE: The aim of this article is to review the available literature on depression in women with metastatic breast cancer in terms of prevalence, potential risk factors, and consequences, as well as pharmacological and psychological interventions. METHOD: An extensive review of the literature was conducted. RESULTS: The prevalence of depression appears to be especially elevated in patients with advanced cancer. Many demographic, medical, and psychosocial factors may increase the risk that women will develop depressive symptoms during the course of their illness. Despite the fact that depression appears to be associated with numerous negative consequences, this disorder remains underdiagnosed and undertreated. Both pharmacotherapy and psychotherapy have been found to treat effectively depressive symptoms in this population, but cognitive-behavioral therapy appears to be the most cost-effective approach. SIGNIFICANCE OF RESULTS: Areas for future research are suggested.
OBJECTIVE: The aim of this article is to review the available literature on depression in women with metastatic breast cancer in terms of prevalence, potential risk factors, and consequences, as well as pharmacological and psychological interventions. METHOD: An extensive review of the literature was conducted. RESULTS: The prevalence of depression appears to be especially elevated in patients with advanced cancer. Many demographic, medical, and psychosocial factors may increase the risk that women will develop depressive symptoms during the course of their illness. Despite the fact that depression appears to be associated with numerous negative consequences, this disorder remains underdiagnosed and undertreated. Both pharmacotherapy and psychotherapy have been found to treat effectively depressive symptoms in this population, but cognitive-behavioral therapy appears to be the most cost-effective approach. SIGNIFICANCE OF RESULTS: Areas for future research are suggested.
Authors: Connor J Kinslow; Raj S Rajpara; Cheng-Chia Wu; Samuel S Bruce; Peter D Canoll; Shih-Hsiu Wang; Adam M Sonabend; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Tony J C Wang Journal: J Neurooncol Date: 2017-04-26 Impact factor: 4.130
Authors: Gavin J Dyson; Kate Thompson; Susan Palmer; David M Thomas; Penelope Schofield Journal: Support Care Cancer Date: 2011-02-11 Impact factor: 3.603
Authors: Catherine E Mosher; Courtney Johnson; Maura Dickler; Larry Norton; Mary Jane Massie; Katherine DuHamel Journal: Breast J Date: 2013-03-26 Impact factor: 2.431
Authors: Silke Steinbach; Walter Hundt; Thomas Zahnert; Sabina Berktold; Christina Böhner; Nina Gottschalk; Moritz Hamann; Monika Kriner; Petra Heinrich; Barbara Schmalfeldt; Nadia Harbeck Journal: Support Care Cancer Date: 2009-06-03 Impact factor: 3.603
Authors: Jennifer A Shin; Areej El-Jawahri; Amanda Parkes; Stephen M Schleicher; Helen P Knight; Jennifer S Temel Journal: J Palliat Med Date: 2016-04-28 Impact factor: 2.947
Authors: Timothy J Williamson; Susan M Love; Jessica N Clague DeHart; Alexandra Jorge-Miller; Leah Eshraghi; Heather Cooper Ortner; Annette L Stanton Journal: Breast Cancer Res Treat Date: 2018-05-16 Impact factor: 4.872